Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

0 YEARS OLD: RESULTS

OF A PHASE 1 STUDY

Abstract #0515

Poster session 2: Acute myeloid leukemia -- Clinical II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

o A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9

INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

Abstract #0792

Poster session 2: Novel therapies, drug resistance and pharmacology II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

All clinical data presented will be available following each conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling.

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leuke
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ... virus infections, today announced that Jonathan P. ... of Finance, a newly created role.  Mr. Freve ... including financial planning and reporting, accounting and risk ... , President and CEO. Mr. ...
(Date:2/26/2015)... Israel , Feb. 26, 2015 Integrity ... of the GlucoTrack ® model DF-F, a noninvasive  device ... Lutz Heinemann , Ph.D., will head its new ... opinion leaders in the field of Diabetes research, monitoring ... , Ph.D has been Chief Executive Officer and Head, ...
(Date:2/26/2015)... Feb. 26, 2015 The market for ... is estimated at 2.4 billion in 2014.   ... growth, government insurance, newly insured patients and updated ... and will continue to propel demand.  The healthcare market ... the market and interviews with IVD manufacturers and ...
Breaking Medicine Technology:Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4
... Calif., Dec. 12, 2011 Since 1994, the Huntington ... of various specialties, has been providing expert medical care ... accepts almost every major health plan and is affiliated ... HMF is the group,s mission to provide a collaborative ...
... 12, 2011 /PRNewswire-iReach/ -- Thomas Ash was ... Ametros as executive vice president in February 2011. Prior ... compensation managed care industry. He served as vice president ... of national occupational health for Kaiser Permanente, division president ...
Cached Medicine Technology:The Huntington Medical Foundation -- Pasadena's Premier Medical Group 2Ametros Financial Names Thomas Ash as CEO 2
(Date:2/26/2015)... Francisco, CA (PRWEB) February 26, 2015 ... the American College of Traditional Chinese Medicine (ACTCM). ACTCM ... starting off with the Chinese New Year celebration and ... event schedule is as follows: , Sunday, March 1 ... 2:30 p.m., ACTCM celebrates the Chinese New Year with ...
(Date:2/26/2015)... When Cosmetic Town launched in 2012, its ... what will soon be, the cornerstone of work that ... of insight that will be accessible to the public, ... has maintained during its existence. Users have more data ... by visiting the Cosmetic Town Journal’s doctor’s page. There ...
(Date:2/26/2015)... 26, 2015 PartnerTech Inc . has ... Makers Awards finalist. , The Movers & ... in the manufacturing, processing, or distribution of tangible products and ... This annual event serves as Georgia’s largest local awards ... to draw more than 300 local industry and business leaders. ...
(Date:2/26/2015)... 26, 2015 Participants in the ... Working? What’s Not? What’s New? ,” will learn ... to achieve strong outcomes for duals-plan members and ... in the implementation phase of programs for Medicare-Medicaid ... Which ones need to be implemented in the ...
(Date:2/26/2015)... 26, 2015 The hip resurfacing procedure ... and Central Texas resident John Short to resume his active ... set out to climb Mt. Kilimanjaro, the highest free-standing mountain ... trafficking. , Starting in his late 20s, Short suffered from ... hip bones and sockets were bone on bone. , ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces March Schedule of Events 2Health News:Cosmetic Town has now Recreated Itself by Adding New Features 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 3Health News:Upcoming AIS Virtual Conference Will Explain What Is and Is Not Working in Medicare-Medicaid Dual Eligibles Programs 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3
... Association (AGA) Research Foundation has announced the 2011 ... Eli and Edythe Broad Foundation, the awards are ... digestive diseases. "At a time of ... are critical for the future of gastroenterology research, ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) -- ... the same time they,re having a uterine aspiration due to ... compared to women offered one later on, new research suggests. ... for IUDs inserted immediately after a uterine aspiration is higher ...
... of "pay-for-performance" bonuses to try to reduce racial and ethnic ... no evidence of the problem at any of the state,s ... questions about the effectiveness of the state,s novel approach. ... Health Affairs (June 9, 2011), found that racial and ...
... as an intrauterine device or IUD immediately following a first ... have an unintended pregnancy than those who delay getting an ... Oregon Health & Science University. The findings are ... Medicine . Research has shown that IUDs are safe, ...
... , WEDNESDAY, June 8 (HealthDay News) -- Jogging, ... protect the brain from "silent strokes," or small brain lesions ... of a future stroke, a new study suggests. "These ... they have been associated with an increased risk of falls ...
... of Sheffield have discovered valuable insight into how people ... in the UK. The team, from the University,s ... Lymphoma Research, Biotechnology and Biological Sciences Research Council (BBSRC) ... to that previously thought to be the cause of ...
Cached Medicine News:Health News:Outstanding high school students receive AGA Research Foundation Fellowship Awards 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 2Health News:It's Safe to Get IUD Right After Abortion, Miscarriage: Study 3Health News:Pioneering hospital pay-for-performance program falls short of its goals 2Health News:Immediate use of an IUD following abortion more likely to prevent unintended pregnancies 2Health News:Exercise May Protect the Brain From 'Silent Strokes' 2Health News:New research provides breakthrough in understanding common cancer 2
... FlexSure HP is a visually read, qualitative ... to H. pylori, a bacterium that grows ... peptic ulcer disease and some gastric cancers. ... whole blood or serum samples, provides the ...
Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
A simple, in-office test for the detection of mononucleosis. Easy to use with fast, accurate results within minutes....
Medicine Products: